EWSR1 and acute lymphoblastic leukemia: TAE226 has shown anti-tumor effects in preclinical in vivo and in vitro assays in non-small cell lung cancer (NSCLC) [34], Ewing’s Sarcoma (EWS) [35], Ph+Acute lymphoblastic leukemia (Ph+ALL) [36], oral squamous cell carcinoma (OSCC) [37], colorectal carcinoma [38] and pancreatic ductal adenocarcinoma (PDAC) [39].